NO301013B1 - Ketorolac-derivater med betydelig redusert gastrointestinal irritasjon og ulcerasjon - Google Patents
Ketorolac-derivater med betydelig redusert gastrointestinal irritasjon og ulcerasjon Download PDFInfo
- Publication number
- NO301013B1 NO301013B1 NO940109A NO940109A NO301013B1 NO 301013 B1 NO301013 B1 NO 301013B1 NO 940109 A NO940109 A NO 940109A NO 940109 A NO940109 A NO 940109A NO 301013 B1 NO301013 B1 NO 301013B1
- Authority
- NO
- Norway
- Prior art keywords
- ketorolac
- ethyl ester
- ulceration
- pharmaceutically acceptable
- pyrrolidinyl
- Prior art date
Links
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical class OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 title claims description 26
- 208000025865 Ulcer Diseases 0.000 title description 12
- 230000036269 ulceration Effects 0.000 title description 10
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 title description 3
- -1 2-(1-pyrrolidinyl) ethyl Chemical group 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical group OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 description 20
- 230000000694 effects Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 9
- 230000000202 analgesic effect Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000001741 anti-phlogistic effect Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229940049920 malate Drugs 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010062065 Perforated ulcer Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical class [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4300697A DE4300697C1 (de) | 1993-01-13 | 1993-01-13 | Keterolac-Derivat mit wesentlich geringerer gastrointestinaler Reizung und Ulzeration |
Publications (3)
Publication Number | Publication Date |
---|---|
NO940109D0 NO940109D0 (no) | 1994-01-12 |
NO940109L NO940109L (no) | 1994-07-14 |
NO301013B1 true NO301013B1 (no) | 1997-09-01 |
Family
ID=6478109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO940109A NO301013B1 (no) | 1993-01-13 | 1994-01-12 | Ketorolac-derivater med betydelig redusert gastrointestinal irritasjon og ulcerasjon |
Country Status (14)
Country | Link |
---|---|
US (2) | US5508301A (fi) |
EP (1) | EP0606657B1 (fi) |
JP (1) | JPH06316577A (fi) |
KR (1) | KR940018387A (fi) |
AT (1) | ATE144775T1 (fi) |
CA (1) | CA2113226A1 (fi) |
DE (2) | DE4300697C1 (fi) |
DK (1) | DK0606657T3 (fi) |
ES (1) | ES2094454T3 (fi) |
FI (1) | FI105919B (fi) |
GR (1) | GR3021717T3 (fi) |
HU (1) | HU216841B (fi) |
NO (1) | NO301013B1 (fi) |
ZA (1) | ZA94183B (fi) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020050188A (ko) * | 2002-03-19 | 2002-06-26 | 에코바이오젠주식회사 | 경피흡수제로서의 용도를 위해 지용성이 부가된케토로락의 에스테르 유도체 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4089969A (en) * | 1976-07-14 | 1978-05-16 | Syntex (U.S.A.) Inc. | 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof |
JPS539788A (en) * | 1976-07-14 | 1978-01-28 | Syntex Inc | 55aloyll1*22dihydroo3hh pyroro *1*22a* pyroll11 carboxylic acid derivative |
ZA882957B (en) * | 1987-04-27 | 1989-12-27 | Syntex Pharma Int | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal anti-inflammatory drugs |
DK0519983T3 (da) * | 1990-03-16 | 1996-10-14 | Procter & Gamble | Anvendelse af ketorolac til behandling af periodontal sygdom |
-
1993
- 1993-01-13 DE DE4300697A patent/DE4300697C1/de not_active Expired - Fee Related
- 1993-12-30 DK DK93121130.4T patent/DK0606657T3/da active
- 1993-12-30 AT AT93121130T patent/ATE144775T1/de active
- 1993-12-30 EP EP93121130A patent/EP0606657B1/de not_active Expired - Lifetime
- 1993-12-30 DE DE59304359T patent/DE59304359D1/de not_active Expired - Fee Related
- 1993-12-30 ES ES93121130T patent/ES2094454T3/es not_active Expired - Lifetime
-
1994
- 1994-01-03 HU HU9400006A patent/HU216841B/hu not_active IP Right Cessation
- 1994-01-07 US US08/178,541 patent/US5508301A/en not_active Expired - Fee Related
- 1994-01-11 CA CA002113226A patent/CA2113226A1/en not_active Abandoned
- 1994-01-12 ZA ZA94183A patent/ZA94183B/xx unknown
- 1994-01-12 JP JP6013935A patent/JPH06316577A/ja active Pending
- 1994-01-12 KR KR1019940000417A patent/KR940018387A/ko not_active Application Discontinuation
- 1994-01-12 NO NO940109A patent/NO301013B1/no unknown
- 1994-01-13 FI FI940171A patent/FI105919B/fi active
-
1995
- 1995-06-06 US US08/468,648 patent/US5574170A/en not_active Expired - Fee Related
-
1996
- 1996-11-20 GR GR960403112T patent/GR3021717T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2113226A1 (en) | 1994-07-14 |
FI105919B (fi) | 2000-10-31 |
GR3021717T3 (en) | 1997-02-28 |
DK0606657T3 (da) | 1997-04-14 |
DE4300697C1 (de) | 1994-05-19 |
FI940171A (fi) | 1994-07-14 |
ES2094454T3 (es) | 1997-01-16 |
HUT70410A (en) | 1995-10-30 |
EP0606657A1 (de) | 1994-07-20 |
DE59304359D1 (de) | 1996-12-05 |
HU9400006D0 (en) | 1994-05-30 |
KR940018387A (ko) | 1994-08-16 |
US5508301A (en) | 1996-04-16 |
ATE144775T1 (de) | 1996-11-15 |
US5574170A (en) | 1996-11-12 |
HU216841B (hu) | 1999-09-28 |
NO940109D0 (no) | 1994-01-12 |
JPH06316577A (ja) | 1994-11-15 |
NO940109L (no) | 1994-07-14 |
ZA94183B (en) | 1994-08-18 |
EP0606657B1 (de) | 1996-10-30 |
FI940171A0 (fi) | 1994-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2745436B2 (ja) | フェニルアルカン酸誘導体、その製造方法並びにその光学異性体の分離方法 | |
JP3305315B2 (ja) | 動物及び人間の疼痛及び/又は炎症の抑制時における薬剤ならびにその製造及びその使用 | |
JPH07507057A (ja) | 解熱鎮痛方法および光学的に純粋なr(‐)ケトプロフェンを含有する組成物 | |
AU696620B2 (en) | Antipyretic and analgesic methods and compositions containing optically pure R-ketorolac | |
PL175265B1 (pl) | Nowa pochodna arylopropionowa sól trometaminowa kwasu (+)-S-2-(3-benzoilofenylo)propionowego, sposób jej wytwarzania i kompozycja farmaceutyczna | |
SK279279B6 (sk) | S(-)-nátrium-2-(4-izobutylfenyl)propionát-dihydrát | |
JPH0656699A (ja) | 新規な非ステロイド系抗炎症、鎮痛及び/又は解熱作用を有する物質及びそれらを含有する医薬品組成物 | |
JPS56145298A (en) | Aminophenyl derivative and physiologically active preparation containing the same | |
NZ240616A (en) | Hydrogen-bridge-bound complexes comprising a 1:1 stoichiometric proportion of s(+) phenylalkanoic acid and an amino sugar; preparatory processes and pharmaceutical compositions | |
WO1991006295A1 (en) | Analgesic composition containing optically pure s(+) flurbiprofen | |
US20220401423A1 (en) | Methods for treating inflammatory bowel disease | |
NO301013B1 (no) | Ketorolac-derivater med betydelig redusert gastrointestinal irritasjon og ulcerasjon | |
CA1107199A (en) | Drug-combinations and processes of their preparation | |
KR0175345B1 (ko) | 장점막 장애 예방 및 치료제 | |
US4134989A (en) | Guaiacol p-isobutyl hydratropate | |
CA2398219A1 (en) | Dual inhibitors of cholesterol ester and wax ester synthesis for sebaceous gland disorders | |
ES2358564T3 (es) | Derivados de carbonilamino útiles para el tratamiento de una enfermedad inflamatoria intestinal. | |
JPH07504410A (ja) | (r)−2−(3−ベンゾイルフェニル)プロピオン酸を含有する鎮痛剤として有用な薬学的組成物 | |
KR970011456B1 (ko) | d-2-(6-메톡시-2-나프틸)-프로피온산의 광학활성 유도체와 이것을 함유한 약제학적 조성물 | |
RU2160102C2 (ru) | Применение бензидамина для лечения патологических состояний, вызванных фно | |
HU210203A9 (hu) | Lényegesen kevesebb gasztrointesztinális irritációt és fekélyképződést okozó ketorolak-származékok Az átmeneti oltalom az 1-2.. igénypontra vonatkozik. | |
GB2117238A (en) | Morniflumate pharmaceutical compositions having antiinflammatory, analgesic, antipyretic and gastroprotective activity | |
US4812482A (en) | Application of α-[[(2-hydroxy-1, 1-dimethyl-ethyl) amine] methyl] benzene methanol hydrochloride (EL-508) as a drug with antiinflammatory action | |
US5055488A (en) | 3-methyl-3-(4-acetylaminophenoxy)-2,4-dioxabenzocyclohexanone-1 and a pharmaceutical composition containing the same | |
JPH035425A (ja) | 抗潰瘍剤 |